Intrusive thoughts and distress following amyloid status disclosure in a preclinical Alzheimer’s disease trial: Comparisons across racial and ethnic groups

Preclinical Alzheimer’s disease (AD) trials require biomarker testing and disclosure. Efforts are underway to improve the diversity and inclusivity of enrollment in these trials. While previous studies have shown that disclosure can be performed safely, trialists need a more thorough understanding of whether reactions to AD biomarker disclosure differ among racial and ethnic groups.